Telix Appoints David Gill as Non-Executive Director Effective May 11, 2026
Telix adds David Gill as Non-Executive Director effective May 11, 2026, slated to succeed Chair Mark Nelson. Gill brings 35+ years of life sciences leadership, including CFO of EndoChoice and board roles at Evolus and others, bolstering governance for dual-listed expansion.
1. Appointment Details
Telix Pharmaceuticals has expanded its board by appointing David Gill as Non-Executive Director, with the role commencing on May 11, 2026. This move aligns with succession planning, positioning Gill to succeed Interim Chair Mark Nelson, who will remain on the board in a non-executive capacity.
2. Executive Background
David Gill offers over 35 years of senior leadership in biopharmaceuticals and medical devices, having served as CFO or President at EndoChoice Holdings and CTI Molecular Imaging, among others. His board experience spans Evolus, Allucent, Bridge to Life and additional firms, bringing deep expertise in capital markets, scaling businesses and corporate turnaround strategies.